Y
Yuehui Wu
Researcher at GlaxoSmithKline
Publications - 15
Citations - 616
Yuehui Wu is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Trametinib & Pharmacodynamics. The author has an hindex of 10, co-authored 15 publications receiving 459 citations. Previous affiliations of Yuehui Wu include Merck & Co. & Research Triangle Park.
Papers
More filters
Journal ArticleDOI
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina Anne Piha-Paul,Christine L. Hann,Christopher A. French,Sophie Cousin,Irene Brana,P. A. Cassier,Victor Moreno,Johann S. de Bono,Sara Duckworth Harward,Geraldine Ferron-Brady,Olena Barbash,Anastasia Wyce,Yuehui Wu,Thierry Horner,Meg Annan,Nigel J. Parr,Rabinder K Prinjha,Christopher L. Carpenter,John Hilton,David S. Hong,Naomi B. Haas,Mark C. Markowski,Arindam Dhar,Peter J. O'Dwyer,Geoffrey I. Shapiro,Geoffrey I. Shapiro +25 more
TL;DR: Once-daily molibresib was tolerated at doses demonstrating target engagement in patients with nuclear protein in testis (NUT) carcinoma (NC), and preliminary data indicate proof-of-concept in NC.
Journal ArticleDOI
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
Gautam Borthakur,Leslie Popplewell,Michael Boyiadzis,James M. Foran,Uwe Platzbecker,Norbert Vey,Roland B. Walter,Rebecca L. Olin,Azra Raza,Aristoteles Giagounidis,Aref Al-Kali,Elias Jabbour,Tapan M. Kadia,Guillermo Garcia-Manero,John W. Bauman,Yuehui Wu,Yuan Liu,Dan Schramek,Donna S. Cox,Paul Wissel,Hagop M. Kantarjian +20 more
TL;DR: Tametinib, a mitogen‐activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias.
Journal ArticleDOI
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).
Chloe E. Atreya,Eric Van Cutsem,Johanna C. Bendell,Thierry André,Jan H.M. Schellens,Michael S. Gordon,Autumn J. McRee,Peter J. O'Dwyer,Kei Muro,Josep Tabernero,Robin M.J.M. van Geel,Roger Sidhu,James G. Greger,Fatima A. Rangwala,Monica Motwani,Yuehui Wu,Keith W. Orford,Ryan B. Corcoran +17 more
TL;DR: Preclinical data suggest that BRAF V600E mutations occur in 5–10% of mCRC and confer a poor prognosis and should be considered a major concern for future BRAFm melanoma research.
Journal ArticleDOI
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
Johanna C. Bendell,Chloe E. Atreya,Thierry André,Josep Tabernero,Michael S. Gordon,René Bernards,Eric Van Cutsem,Sabine Tejpar,Roger Sidhu,William Y. Go,Alicia Allred,Monica Motwani,Benjamin B. Suttle,Yuehui Wu,Axel Hoos,Keith W. Orford,Ryan B. Corcoran,Jan H.M. Schellens +17 more
TL;DR: The BRAF V600 mutations occur in 5–10% of CRC and confer poor prognosis and unlike in BRAF mutant (BRAFm) melanoma, BRAF and MEK inhibitors show limited activity in BRAfm CRC.
Journal ArticleDOI
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Juneko E. Grilley-Olson,Philippe L. Bedard,Angelica Fasolo,Cornfeld Mark J,Cornfeld Mark J,Cornfeld Mark J,Leanne Cartee,Leanne Cartee,Albiruni Ryan Abdul Razak,Lee-Anne Stayner,Yuehui Wu,Yuehui Wu,R. Greenwood,R. Greenwood,R. Greenwood,Rajeshwar Singh,Rajeshwar Singh,Carrie B. Lee,Johanna C. Bendell,H. A. Burris,G. Del Conte,Cristiana Sessa,J. R. Infante +22 more
TL;DR: GSK458 plus trametinib is poorly tolerated, due to skin and GI-related toxicities, which may be due to overlapping toxicities precluding sufficient dose exposure.